These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 21139098)

  • 21. Exploiting epigenetic dependencies in ovarian cancer therapy.
    Coughlan AY; Testa G
    Int J Cancer; 2021 Nov; 149(10):1732-1743. PubMed ID: 34213777
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SMARCB1 gene with a 27-base pair (bp) deletion is not a mutation.
    Sano K; Matsuda K; Yoichi K
    Cancer Genet Cytogenet; 2010 May; 199(1):65. PubMed ID: 20417873
    [No Abstract]   [Full Text] [Related]  

  • 23. Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance.
    Kikuchi J; Kinoshita I; Shimizu Y; Kikuchi E; Konishi J; Oizumi S; Kaga K; Matsuno Y; Nishimura M; Dosaka-Akita H
    Cancer; 2010 Jun; 116(12):3015-24. PubMed ID: 20564407
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Chemical targeting of DNA and histone methylation in cancer: Novelties, hopes and promises].
    Bon C; Erdmann D; Halby L; Arimondo PB
    Bull Cancer; 2019 Oct; 106(10):823-833. PubMed ID: 31522746
    [No Abstract]   [Full Text] [Related]  

  • 25. Clear cell carcinoma of ovary and uterus.
    Glasspool RM; McNeish IA
    Curr Oncol Rep; 2013 Dec; 15(6):566-72. PubMed ID: 24114188
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Histone H3 modifications associated with differentiation and long-term culture of mesenchymal adipose stem cells.
    Noer A; Lindeman LC; Collas P
    Stem Cells Dev; 2009 Jun; 18(5):725-36. PubMed ID: 18771397
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epigenetic control of hematopoietic stem cell aging the case of Ezh2.
    De Haan G; Gerrits A
    Ann N Y Acad Sci; 2007 Jun; 1106():233-9. PubMed ID: 17332078
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A novel mutation of the SMARCB1 gene in a case of extrarenal malignant rhabdoid tumor.
    Koitabashi M; Kanazawa T; Tamura K; Tsukada S; Suzuki M; Morikawa A; Ogawa C; Hirado J
    Cancer Genet Cytogenet; 2008 Feb; 181(1):67-8. PubMed ID: 18262058
    [No Abstract]   [Full Text] [Related]  

  • 29. Ovarian cancer: new developments in clear cell carcinoma and hopes for targeted therapy.
    Yamashita Y
    Jpn J Clin Oncol; 2015 May; 45(5):405-7. PubMed ID: 25583423
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of Polycomb-group genes in human ovarian follicles, oocytes and preimplantation embryos.
    Hinkins M; Huntriss J; Miller D; Picton HM
    Reproduction; 2005 Dec; 130(6):883-8. PubMed ID: 16322547
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epigenetic targeting in pancreatic cancer.
    van Kampen JG; Marijnissen-van Zanten MA; Simmer F; van der Graaf WT; Ligtenberg MJ; Nagtegaal ID
    Cancer Treat Rev; 2014 Jun; 40(5):656-64. PubMed ID: 24433955
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Re: Infrequent SMARCB1/INI1 gene alteration in epithelioid sarcoma: a useful tool in distinguishing epithelioid sarcoma from malignant rhabdoid tumor: Direct evidence of mutational inactivation of SMARCB1/INI1 in epithelioid sarcoma.
    Flucke U; Slootweg PJ; Mentzel T; Pauwels P; Hulsebos TJ
    Hum Pathol; 2009 Sep; 40(9):1361-2; author reply 1362-4. PubMed ID: 19683621
    [No Abstract]   [Full Text] [Related]  

  • 33. [An "ariditary" form of ovarian cancer].
    Birnbaum DJ; Sabatier R; Mamessier É; Birnbaum D; Bertucci F
    Med Sci (Paris); 2010 Dec; 26(12):1040-2. PubMed ID: 21187041
    [No Abstract]   [Full Text] [Related]  

  • 34. Developing EZH2-Targeted Therapy for Lung Cancer.
    Frankel AE; Liu X; Minna JD
    Cancer Discov; 2016 Sep; 6(9):949-52. PubMed ID: 27587466
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Promises and challenges of anticancer drugs that target the epigenome.
    Verbrugge I; Johnstone RW; Bots M
    Epigenomics; 2011 Oct; 3(5):547-65. PubMed ID: 22126246
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The polycomb group protein enhancer of zeste homolog 2 (EZH 2) is an oncogene that influences myeloma cell growth and the mutant ras phenotype.
    Croonquist PA; Van Ness B
    Oncogene; 2005 Sep; 24(41):6269-80. PubMed ID: 16007202
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Molecular characterisation of SMARCB1 and NF2 in familial and sporadic schwannomatosis: an evolving paradigm].
    Dereure O
    Ann Dermatol Venereol; 2009 Mar; 136(3):296-7. PubMed ID: 19328320
    [No Abstract]   [Full Text] [Related]  

  • 38. Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features.
    van Leenders GJ; Dukers D; Hessels D; van den Kieboom SW; Hulsbergen CA; Witjes JA; Otte AP; Meijer CJ; Raaphorst FM
    Eur Urol; 2007 Aug; 52(2):455-63. PubMed ID: 17134822
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mutational analysis of EZH2 codon 641 in non-Hodgkin lymphomas and leukemias.
    Park SW; Chung NG; Eom HS; Yoo NJ; Lee SH
    Leuk Res; 2011 Jan; 35(1):e6-7. PubMed ID: 20863566
    [No Abstract]   [Full Text] [Related]  

  • 40. DNA methylation and complete transcriptional silencing of cancer genes persist after depletion of EZH2.
    McGarvey KM; Greene E; Fahrner JA; Jenuwein T; Baylin SB
    Cancer Res; 2007 Jun; 67(11):5097-102. PubMed ID: 17545586
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.